News

While it trails Johnson & Johnson’s Tecvayli, Regeneron still hopes Lynozyfic can differentiate in terms of dosing ...
Several companies on the Wall Street have seen some Seeking Alpha analyst activity, including both upgrades and downgrades in ...
UBS has decided Regeneron Pharmaceuticals needs a new wardrobe, trimming its price target from $633 to a more modest $560.
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is among the 11 Best Genomics Stocks to Buy According to Hedge Funds. UBS has ...
[Click here for information about joining the class action] On May 30, 2025, Sanofi issued a press release announced mixed data from a Phase 3 program for itepekimab, an antibody therapy targeting the ...
Regeneron Pharmaceuticals (NASDAQ:REGN) shares witnessed a notable 19% decline on Friday, May 30, in the wake of the unexpected failure of itepekimab, its chronic obstructive pulmonary disease ...
Sanofi and Regeneron have reported that the Phase III AERIFY-1 trial of the fully human monoclonal antibody itepekimab.
Itepekimab met the primary endpoint in one of two COPD phase 3 studies AERIFY-1 study met its primary endpoint of a statistically significant reduction in moderate or severe exacerbations in former ...
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) faced a turbulent week as its shares plunged 17%, despite announcing encouraging results from a Phase 3 trial of itepekimab for chronic obstructive ...